PET Imaging for Alzheimer's Disease
(ADRC PET Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to further engage and characterize Alzheimer's Disease Research Center (ADRC) participants through additional research opportunities, particularly PET imaging. Amyloid and Tau PET imaging will be collected in 24 participants per year, for a total of 120 participants over five years.
All participants will be followed longitudinally, including through potential transitions from normal aging to mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD).
Who Is on the Research Team?
Patrick J Lao, PhD
Principal Investigator
Columbia University
Are You a Good Fit for This Trial?
What Are the Treatments Tested in This Trial?
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants with Alzheimer's disease and related disorders, including but not limited to: Frontotemporal dementia, Lewy Body dementia, Creutzfeldt-Jakob disease, other dementias, and subjective or objective features of mild cognitive change.
Healthy elderly controls and nonpatient volunteers with subjective or objective features of normal aging.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Patrick Lao
Lead Sponsor
National Institute on Aging (NIA)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.